A study conducted by trial tech firms Curedatis and Climedo Health reveals what trial professionals view as challenges and opportunities in digitalization.
The International Vaccine Institute (IVI) and Bharat Biotech have started a Phase 2/3 clinical trial for a chikungunya vaccine candidate in Costa Rica.
The CRO has launched an initiative that offers help navigating regulatory issues for ultra-rare disease patient advocacy groups that demonstrate a need.
The drug discovery company reportedly used AI-powered drug discovery to come up with a promising preclinical candidate for treatment of the kidney ailment.
The two firms will work together on solutions to connect de-identified, first-party data to real-world data to help advance precision medicine development.
The digital pathology firm and image-analysis software developer will partner on artificial intelligence based solutions to improve trial decision making.
The US Food and Drug Administration continues to review potential preventatives and treatments for the virus, and to offer advice to life-sciences professionals and civilians alike.
The patient matching platform firm will work with Precision for Medicine on solutions to increase diversity, elevate enrollment and speed new therapies.
An executive from the digital therapeutics specialist discusses the clinical trial landscape, and how clinical care can yield a number of important benefits.
A leader from Veeva Systems shares perspective on what factors are impacting clinical trial data management, and how the industry can adapt to the changes.
This month’s roundup of equipment, decentralized technology, partnerships and other items includes news from Medidata, PerkinElmer, Syneos and other firms.
The National Institute on Aging has launched Outreach Pro, an online tool aimed to help connect with underrepresented populations for Alzheimer’s trials.
The check-in with nearly 1,800 US healthcare consumers reflects how COVID-19 and other factors have impacted patient access, equity, experience and trust.
The World Health Organization’s Solidarity PLUS trial will kick off in 52 countries, trialing three drugs to treat patients hospitalized with COVID-19.
The Heart of Athletes study, using Deloitte’s ConvergeHealth MyPath for Clinical platform, aims to examine heart inflammation in athletes with the virus.
The clinical study network is partnering with the Wisconsin-based health system to increase the reach of trials into a largely rural patient population.
The pharma firm is working with five US colleges and universities onto create programming designed to boost recruitment of Black talent in the industry
A leader from Longboat by Advarra outlines what it really means for a study to be patient centric, and how to succeed in achieving patient-centric trials.
Producers of CPhI North America 2021 offer a glimpse at programming, including sessions on COVID-19 challenges, supply chain issues, and more key topics.
The Psychae Institute, established by a global team of scientists, will conduct pre-clinical and clinical research around psychedelic medicine development.
The drug, intended for adult patients with moderate-to-severe systemic lupus erythematosus, is the only new therapy approved for SLE in more than a decade.
The two companies are collaborating to research, develop and launch new small-molecule drug candidates aimed at treating obesity and related comorbidities.
A leader from the topical solutions centered CDMO discusses the differences between approaches by the FDA and EMA, and how to deal with them effectively.
The BiovitalsHF, from Biofourmis, is intended to augment decision-making in clinical environments, and to supplement traditional pharmaceutical therapies.
A recent check-in with several biopharma and CRO companies, conducted by Life Science Strategy Group, indicates adjustment to pandemic-related challenges.
The two pharma firms will partner to study the efficacy of Opdivo, paired with a SHP2 inhibitor, to treat non-small cell lung cancer with KRAS mutations.
A clinical trial logistics expert discusses specialized concerns involved in transporting cell and gene products and other personalized medicine items.
A new UK eLearning program is targeted at healthcare and academic professionals to support their learning on advanced therapy medicinal products (ATMPs).
The health data specialist and pharma firm are partnering on solutions around remote collection of digital data for detection and monitoring of treatments.
A leader from the artificial intelligence solutions firm discusses how advanced analytical tools can help researchers make the most of mountains of data.
The World Health Organization hopes to encourage the development of novel therapies for tuberculosis by spotlighting key clinical study characteristics.
Eli Lilly and Company and Banner Alzheimer’s Institute have announced a strategic research collaboration as part of the planned Phase 3 study for donanemab in participants at risk from cognitive and functional decline related to Alzheimer’s disease.
The past several days have seen a relatively large number of industry acqusitions, with Lilly, Phillip Morris, WCG, CTI and others making notable buys.
A representative from the medication management solutions company suggests patient behavior data can be used to improve adherence to trial drug regimens.
A leader from the clinical tech consultancy shares advice on how to employ training to help keep up with the rapidly evolving field of data management.
The two companies will work together to come up with solutions that use machine learning and artificial intelligence to help accelerate innovation in R&D.
According to a leader from CRO Quanticate, the research industry’s increased use of real-world data is leading to a broad range of benefits in trial work.
A leader from life-sciences IT consultancy Daelight Solutions shares how the clinical trial data landscape has changed and offers advice on how to keep up.
Antibody responses against the SARS-CoV-2 spike protein were found in 99% of volunteers after the second dose of ReiThera’s COVID-19 vaccine candidate, according to Phase 2 preliminary data.
The agency’s effort to fight the deadly disease now includes taps the pharma company’s testing tools to help speed up diagnosis and grow treatment access.
Acting US FDA commissioner, Janet Woodcock, has called for an independent federal review of interactions between officials at her agency and representatives of Biogen, prior to the recent approval of the pharma company’s treatment for Alzheimer’s disease....
During the Rare/Orphan Diseases, Special Patient Population webinar, a group of industry experts discussed challenges and opportunities faced in the field.
